Cipla Limited has launched Yurpeak (tirzepatide), a once‑weekly injectable therapy for adults with obesity or type‑2 diabetes mellitus, marking a major step forward in India’s fight against metabolic disease.
Yurpeak is the second brand of Tirzepatide in India, marketed under a new collaborative agreement between Cipla and Eli Lilly and Company designed to expand access beyond urban centres.
Tirzepatide works as a dual‑agonist of the GIP and GLP‑1 receptors, helping regulate blood sugar and support weight management — intended as an adjunct to diet and exercise for people with type‑2 diabetes or chronic obesity (BMI ≥ 30, or BMI ≥ 27 with at least one weight‑related comorbidity).
Yurpeak will be available on prescription in pre‑filled KwikPen injectors, across six dosage strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg), enabling physicians to tailor therapy to patient needs.
Through its wide distribution network, Cipla aims to reach smaller towns and semi‑urban regions, extending the availability of this advanced treatment beyond major cities, and potentially addressing India’s high burden of diabetes and obesity.
To support safe and effective use, Cipla will roll out patient‑education programmes covering proper dosing, self‑administration, and informed consultations with healthcare professionals.
